Athernal Bio
PrivateLast Round
VC Round
Oct 1, 2025
Total Funding Raised
$12,600
Company Overview
Athernal Bio is a biotechnology company developing targeted immunotherapies for high-risk clonal haematopoiesis, a blood cancer precursor condition, with the goal of preventing cancer before it starts.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Athernal Bio Comparables
Compare Athernal Bio with similar companies based on industry and business-model similarity.
Athernal Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Oct 1, 2025 | ||||
| Accelerator | May 30, 2024 |
Key People
Founding team and executive leadership
Athernal Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Accelerate@Babraham | Accelerator |
| Delin Ventures | VC Round |
Athernal Bio Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Athernal Bio's valuation, stock price, and market status.